CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Ocata Therapeutics Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Ocata Therapeutics Inc.
33 Locke Drive
Phone: (508) 756-1212p:508 756-1212 Marlborough, MA  01752-1167  United States Ticker: OCATOCAT
This company was Merged or Acquired on 2/9/2016.
This company ceased filing statements with the SEC on 2/22/2016.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Ocata Therapeutics, Inc., formerly Advanced Cell Technology, Inc., is a biotechnology company focused on the development and commercialization of Regenerative Ophthalmology therapeutics. The Company's advanced products are in clinical trials for the treatment of Stargardt's macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. The Company is also developing several pre-clinical terminally differentiated-cell therapies for the treatment of other ocular disorders. Additionally, it has a number of pre-clinical stage assets in disease areas outside the field of ophthalmology, including autoimmune, inflammatory and wound healing-related disorders.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/201512/31/2014YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Michael T.Heffernan 50 1/22/2014 4/11/2012
President, Chief Executive Officer, Director Paul K.Wotton 54 7/31/2014 7/21/2014
Chief Financial Officer, Chief Operating Officer EdwardMyles 43 7/21/2014 6/12/2013
9 additional Officers and Directors records available in full report.

Business Names
Business Name
A.C.T. Holdings Inc.
A.C.T. Holdings, Inc.
Advanced Cell Technology, Inc.
Mytogen, Inc.
OCAT
TWO MOONS KACHINAS CORP

General Information
Number of Employees: 37 (As of 12/31/2014)
Outstanding Shares: 42,300,462 (As of 10/30/2015)
Shareholders: 223
Stock Exchange: NASD
Federal Tax Id: 870656515
Fax Number: (508) 229-2333


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023